<DOC>
	<DOCNO>NCT02853110</DOCNO>
	<brief_summary>The hypo-FLAME study multicenter phase II study ( n=100 ) investigate whether focal SBRT boost MRI-defined macroscopic tumor volume feasible associate acceptable toxicity addition whole gland prostate SBRT .</brief_summary>
	<brief_title>Hypofractionated Focal Lesion Ablative Microboost prostatE Cancer</brief_title>
	<detailed_description>Rationale : Hypofractionation stereotactic body radiotherapy ( SBRT ) technique prostate cancer produce excellent treatment outcome term survival toxicity much convenient current fractionation scheme . Local recurrence occur frequently site primary dominant tumor location prior treatment . Therefore dose escalation site primary tumor may improve disease control . Objective : The main goal phase II study investigate whether focal ablative SBRT boost macroscopic tumor feasible associate acceptable toxicity addition whole gland prostate SBRT . The secondary objective study : late toxicity , quality life ( QoL ) biochemical disease free survival ( bDFS ) . Furthermore , two side-studies incorporated phase II study : 1 ) weekly MRI perform prepare future MRI-guided ( MR-linac ) treatment without gold fiducial marker 2 ) blood sample translational research ( radiogenomics ) Biobank purpose . Study design : Prospective multicenter interventional study whole gland prostate SBRT use MRI focal boost 100 consecutive intermediate high risk prostate cancer patient . Study population : One hundred patient histologically proven prostate adenocarcinoma intermediate risk high risk disease . Patients refer external beam radiotherapy ( EBRT ) fulfill inclusion criterion without exclusion criterion include present trial write informed consent . Intervention : Patients treat external beam radiotherapy SBRT technique 35 Gy 5 weekly fraction additional simultaneously integrated focal boost tumor nodule ( ) visible MRI 50 Gy . In addition , patient ask undergo 5 additional MRI scan ( ~15 min/scan ) without contrast enhancement prior radiation session well blood sample translational research ( radiogenomics ) Biobank purpose . Main study parameters/endpoints : The primary endpoint study acute gastrointestinal ( GI ) genitourinary ( GU ) toxicity use Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . Secondary endpoint late GI GU toxicity , QoL , bDFS . Simultaneously , two side-studies perform , i.e . prepare MRI-guided radiotherapy blood sample translational research ( radiogenomics ) Biobank purpose .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Men ≥ 18 year histologically confirm prostate adenocarcinoma Intermediaterisk prostate cancer highrisk prostate cancer , define least one follow risk criterion : clinical Tstage T2b , T2c T3a ( define MRI ) T3b le 5 mm invasion seminal vesicle , Gleason sum score ≥ 7 , PSA ≥ 10 ng/mL Prostate tumor nodule visible MRI Ability give write informed consent willingness return followup Prior pelvic radiotherapy , transurethral prostate resection prostatectomy Unsafe gold fiducial marker implantation Contraindications MRI accord Radiology Department guideline ( metal implant , noncompatible cardiac device , allergy Gadolinium , severe renal dysfunction severe claustrophobia ) Evidence lymph node involvement distant metastatic disease Clinical Tstage &gt; T3b ≥ 5 mm invasion seminal vesicle World Health Organization ( WHO ) performance score &gt; 2 International prostate symptom score ( IPSS score ) ≥ 15 PSA &gt; 30 ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MRI , stereotactic body radiotherapy , hypofractionation</keyword>
</DOC>